{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:09:19Z","timestamp":1790186959208,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jchf.2025.02.027","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:48:47Z","timestamp":1751384927000},"page":"102481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognosis After >50% Decline in eGFR in Heart Failure Patients"],"prefix":"10.1016","volume":"13","author":[{"given":"Deewa Zahir","family":"Anjum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Elmegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Hartwell","family":"Garred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-7358","authenticated-orcid":false,"given":"Nina","family":"Nouhravesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Fosbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jchf.2025.02.027_bib1","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1002\/ehf2.14933","article-title":"Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease","volume":"11","author":"Zahir Anjum","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"23","key":"10.1016\/j.jchf.2025.02.027_bib2","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jchf.2025.02.027_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jchf.2025.02.027_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.027_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.jchf.2025.02.027_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jchf.2025.02.027_bib7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.027_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jchf.2025.02.027_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jchf.2025.02.027_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jchf.2025.02.027_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jchf.2025.02.027_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jchf.2025.02.027_bib13","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jchf.2025.02.027_bib14","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jchf.2025.02.027_bib15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.027_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jchf.2025.02.027_bib17","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jacc.2024.08.034","article-title":"Why has it been challenging to modify kidney disease progression in patients with heart failure?","volume":"84","author":"Vaduganathan","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jchf.2025.02.027_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032539","article-title":"Temporal trends in the initiation of dialysis among patients with heart failure with or without diabetes: a nationwide study from 2002 to 2016","volume":"13","author":"Knigge","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jchf.2025.02.027_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41581-023-00748-3","article-title":"GFR slope as a surrogate marker for future kidney failure","volume":"19","author":"Lees","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.jchf.2025.02.027_bib20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.027_bib21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jchf.2024.01.004","article-title":"Trajectories of kidney function in heart failure over a 15-year follow-up","volume":"12","author":"Zamora","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.jchf.2025.02.027_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish civil registration system","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"issue":"7","key":"10.1016\/j.jchf.2025.02.027_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish national patient register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jchf.2025.02.027_bib24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/CLEP.S245060","article-title":"Existing data sources in clinical epidemiology: laboratory information system databases in Denmark","volume":"12","author":"Arendt","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.jchf.2025.02.027_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish national prescription registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"issue":"9","key":"10.1016\/j.jchf.2025.02.027_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2025.02.027_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2019.09.064","article-title":"The Hospital Frailty Risk Score and its association with in-hospital mortality, cost, length of stay and discharge location in patients with heart failure short running title: frailty and outcomes in heart failure","volume":"300","author":"Kwok","year":"2020","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.jchf.2025.02.027_bib28","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/jcm11082193","article-title":"External validation of the hospital frailty-risk score in predicting clinical outcomes in older heart-failure patients in Australia","volume":"11","author":"Sharma","year":"2022","journal-title":"J Clin Med"},{"issue":"10132","key":"10.1016\/j.jchf.2025.02.027_bib29","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jchf.2025.02.027_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jchf.2025.02.027_bib31","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.124.071110","article-title":"Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: comprehensive individual participant-level analysis of 6 randomized clinical trials","volume":"150","author":"Butt","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.027_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamacardio.2021.5151","article-title":"Potential role and limitations of estimated glomerular filtration rate slope assessment in cardiovascular trials","volume":"7","author":"Khan","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.027_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000997","article-title":"Short-term change in eGFR and risk of cardiovascular events","volume":"3","author":"Turin","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.027_bib34","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.1038\/s41598-021-86955-z","article-title":"The impact of baseline glomerular filtration rate on subsequent changes of glomerular filtration rate in patients with chronic kidney disease","volume":"11","author":"Lin","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jchf.2025.02.027_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"16","key":"10.1016\/j.jchf.2025.02.027_bib36","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jchf.2025.02.027_bib37","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2024.08.006","article-title":"Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes","volume":"84","author":"Neuen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jchf.2025.02.027_bib38","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jchf.2025.02.027_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction","volume":"8","author":"McCausland","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.jchf.2025.02.027_bib40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2025.02.027_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure","volume":"85","author":"McCausland","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925003944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925003944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:23:01Z","timestamp":1785554581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925003944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2213177925003944"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.02.027","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis After >50% Decline in eGFR in Heart Failure Patients","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}],"article-number":"102481"}}